ADMA Biologics (ADMA) Soars 11.6% as Firm Denies Short Seller Allegations

Core Viewpoint - ADMA Biologics Inc. has rebounded from a five-day losing streak, rising 11.58% to $9.25 after refuting a short seller's report that accused the company of providing misleading information regarding its growth [1]. Group 1: Company Response - ADMA Biologics denied the claims made by Culper Research regarding the demand for its product Asceniv, asserting that demand has actually increased over the past two years based on data from distributors and customers [2]. - The company also addressed allegations of channel stuffing, clarifying that there was a misunderstanding as distributors are required to maintain safety stock levels to ensure patients do not miss treatments [4]. - ADMA Biologics stated that its financial statements are clean and have been reviewed by independent auditors who provided an unqualified opinion [4]. Group 2: Commitment and Future Outlook - The company expressed its commitment to leading in the manufacturing, marketing, and commercialization of specialty biologic products aimed at preventing and treating infectious diseases in immunocompromised patients, aiming to create long-term value for shareholders [5].